Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Fig. 2

Mean (±SD) serum concentrations of BITS7201A. a Part A, SC cohorts. b Part A, IV cohorts. c Part B, SC cohorts after the Day 1 dose. d Part B, SC cohorts after the Day 57 dose. Concentrations below the limit of quantification (140 ng/mL) were set to zero. aConcentration data after Study Day 15 for 2 subjects in Cohorts H were excluded due to a missed dose on Study Day 29. bCohort I: n = 1; data is shown only through Day 14 because only one subject was enrolled, and PK samples were not collected after Day 15

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us